Studienlage · Detail
Nabilone: an alternative antiemetic for cancer chemotherapy.
Keine Richtungsangabe
Stichproben = 18
Zusammenfassung
Prospektive randomisierte doppelblinde Cross-over-Studie an Kindern (10 Monate bis 17 Jahre) unter emetogener Chemotherapie: verglichen wurde das synthetische Cannabinoid Nabilon mit oralem Domperidon. 18 von 23 Kindern schlossen die Studie ab; unter Nabilon signifikant weniger Erbrechen und Übelkeit, zwei Drittel bevorzugten Nabilon. Nabilon war Domperidon überlegen. Häufigste Nebenwirkungen: Somnolenz und Schwindel (ein Patient mit Halluzinationen). Fazit: Nabilon ist ein wirksames Antiemetikum bei Chemotherapie im Kindesalter. Kleine Stichprobe.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
—
Zitate / Jahr
—
Autoren
Teilen
Abstract
A prospective randomised double blind crossover trial was conducted comparing the new synthetic cannabinoid nabilone with oral domperidone in a group of children receiving repeated identical courses of emetogenic chemotherapy for a variety of malignant diseases. Eighteen of 23 consecutive eligible children, aged 10 months to 17 years, completed the trial. When taking nabilone they experienced significantly fewer vomiting episodes and less nausea, and two thirds expressed a preference for the drug. The most common side effects of treatment with nabilone were somnolence and dizziness, with one patient being disturbed by hallucinations. The results indicate that nabilone is an effective antiemetic for children having chemotherapy, even for young children. It seems to be superior in this respect to domperidone, and although it has a higher incidence of side effects, these are mostly acceptable to patients. It can be recommended as an alternative to conventional antiemetic treatment throughout childhood.
„Was dem Handeln im Weg steht, wird zum Weg.“